Therapeutic agents for the treatment of migraine
US7772244B2 · kind B2 · utility
9Cited by
8References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 28, 2005 |
| Grant date | Aug 10, 2010 |
| Priority date | — |
| Expiry date | Mar 22, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to compounds of Formula (I)as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.